Directory Groups

Eleven Biotherapeutics

Viventia Bio Inc. is a privately held biopharmaceutical company specializing in the discovery and development of a new generation of immunotoxin products offering more beneficial cancer therapies. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide therapies targeted directly to tumor cells, thereby increasing the safety and efficacy of treatment for patients. Viventia is employing its proprietary payload, deBouganin, to create a portfolio of new antibody products directed at proprietary oncology drug targets.

Headquartered in Winnipeg, Canada, Viventia’s 32,000 square foot state-of-the-art laboratories and fully integrated GMP manufacturing facility provide a robust, cost effective, bench to clinic drug development program for the innovative treatment of cancer.


Contact Info

T: 1 204 478 1023
F: 1 204 452 7721
Eleven Biotherapeutics 147 Hamelin Street Winnipeg R3T 3Z1 MB Canada
147 Hamelin Street
Winnipeg R3T 3Z1 MB Canada